<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.themarketsdaily.com/2019/11/25/neurocrine-biosciences-nasdaqnbix-sets-new-1-year-high-at-116-80.html"/>
    <meta property="og:site_name" content="Markets Daily"/>
    <meta property="article:published_time" content="2019-11-25T16:58:43+00:00"/>
    <meta property="og:title" content="Neurocrine Biosciences (NASDAQ:NBIX) Sets New 1-Year High at $116.80"/>
    <meta property="og:description" content="Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $116.80 and last traded at $116.07, with a volume of 10723 shares traded. The stock had previously closed at $114.34. NBIX has been the topic of several research reports. Needham &amp; Company […]"/>
  </head>
  <body>
    <article>
      <h1>Neurocrine Biosciences (NASDAQ:NBIX) Sets New 1-Year High at $116.80</h1>
      <address><time datetime="2019-11-25T16:58:43+00:00">25 Nov 2019, 16:58</time> by <a rel="author">Mitch Edgeman</a></address>
      <p>Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s stock price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $116.80 and last traded at $116.07, with a volume of 10723 shares traded. The stock had previously closed at $114.34.</p>
      <p>NBIX has been the topic of several research reports. Needham &amp; Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a report on Wednesday, July 31st. Piper Jaffray Companies lifted their target price on shares of Neurocrine Biosciences from $111.00 to $116.00 in a research report on Tuesday, November 5th. TheStreet upgraded shares of Neurocrine Biosciences from a “c+” rating to a “b” rating in a research report on Tuesday, November 19th. Canaccord Genuity lifted their target price on shares of Neurocrine Biosciences from $120.00 to $122.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, <a href="http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $106.94.</p>
      <p>The stock’s 50-day moving average price is $100.29 and its 200-day moving average price is $91.75. The company has a market capitalization of $10.48 billion, a price-to-earnings ratio of 526.00, a price-to-earnings-growth ratio of 5.76 and a beta of 1.20. The company has a quick ratio of 6.99, a current ratio of 7.08 and a debt-to-equity ratio of 0.83.</p>
      <p>Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, November 4th. The company reported $0.56 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a return on equity of 5.67% and a net margin of 3.12%. The company had revenue of $222.09 million for the quarter, compared to analyst estimates of $211.31 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. Neurocrine Biosciences’s revenue for the quarter was up 46.3% on a year-over-year basis. On average, equities research analysts anticipate that Neurocrine Biosciences, Inc. will post 0.82 EPS for the current year.</p>
      <p>In related news, insider Malcolm Lloyd-Smith sold 9,956 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $90.85, for a total transaction of $904,502.60. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through <a href="https://www.sec.gov/Archives/edgar/data/914475/000120919119053286/xslF345X03/doc4.xml">the SEC website</a>. Also, insider Julie Cooke sold 987 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $88.56, for a total transaction of $87,408.72. The disclosure for this sale can be found <a href="https://www.sec.gov/Archives/edgar/data/914475/000120919119052596/xslF345X03/doc4.xml">here</a>. Insiders have sold 56,131 shares of company stock worth $5,745,438 over the last quarter. 4.30% of the stock is owned by company insiders.</p>
      <p>Several institutional investors and hedge funds have recently bought and sold shares of NBIX. Nuveen Asset Management LLC bought a new stake in shares of Neurocrine Biosciences during the second quarter worth approximately $64,739,000. Point72 Asset Management L.P. increased its position in shares of Neurocrine Biosciences by 189.4% during the second quarter. Point72 Asset Management L.P. now owns 1,124,684 shares of the company’s stock worth $94,957,000 after acquiring an additional 735,992 shares in the last quarter. Janus Henderson Group PLC increased its position in shares of Neurocrine Biosciences by 6.1% during the second quarter. Janus Henderson Group PLC now owns 9,352,240 shares of the company’s stock worth $789,610,000 after acquiring an additional 540,279 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Neurocrine Biosciences by 7.1% during the second quarter. Perceptive Advisors LLC now owns 4,023,862 shares of the company’s stock worth $339,734,000 after acquiring an additional 265,200 shares in the last quarter. Finally, First Trust Advisors LP increased its position in shares of Neurocrine Biosciences by 18.0% during the second quarter. First Trust Advisors LP now owns 1,277,700 shares of the company’s stock worth $107,876,000 after acquiring an additional 194,643 shares in the last quarter. 95.02% of the stock is owned by institutional investors and hedge funds.</p>
      <p><b>Neurocrine Biosciences Company Profile</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/NBIX/">NASDAQ:NBIX</a>)</p>
      <p>Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.</p>
      <p>Further Reading: <a href="https://www.marketbeat.com/financial-terms/cost-of-equity-business-investors/">What is cost of equity?</a></p>
    </article>
  </body>
</html>